Skip to main content

Table 2 Distribution of the rheumatoid arthritis patients according to the presence of anti-MCV, anti-CCP, and IgM-RF

From: Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

  Anti-CCP-positive
(n = 80), number (percentage)
Anti-CCP-negative
(n = 76), number (percentage)
  Cutoff 20 U/mL Cutoff 28 U/mL Cutoff 20 U/mL Cutoff 28 U/mL
Anti-MCV     
   Positive 75 (93.75) 71 (88.75) 14 (18.4) 9 (11.8)
   Negative 5 (6.25) 9 (11.25) 62 (81.6) 67 (88.2)
RF+     
   Anti-MCV+ 65 (81.25) 61 (76.25) 5 (6.6) 3 (3.9)
   Anti-MCV- 1 (3.75) 5 (6.25) 8 (10.5) 10 (13.2)
RF-     
   Anti-MCV+ 10 (12.5) 10 (12.5) 9 (11.8) 6 (7.9)
   Anti-MCV- 4 (5) 4 (5) 54 (71.1) 57 (75)
  1. Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor.